Search Results - "Mullins, E. S."

Real‐world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A by Dunn, A. L., Ahuja, S. P., Mullins, E. S.

“…Introduction Prophylaxis with extended half‐life factor VIII (FVIII) is approved for haemophilia A, but data regarding routine clinical use are limited. Aim To…”
Get full text

Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A by Mullins, E. S., Stasyshyn, O., Alvarez‐Román, M. T., Osman, D., Liesner, R., Engl, W., Sharkhawy, M., Abbuehl, B. E.

“…Introduction Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended…”
Get full text

Subcutaneous diphtheria and tetanus vaccines in children with haemophilia: A pilot study and review of the literature by Schaefer, B. A., Gruppo, R. A., Mullins, E. S., Tarango, C.

“…Introduction Subcutaneous (SQ) vaccination has emerged as standard of care in children with severe bleeding disorders to reduce unnecessary factor exposure and…”
Get full text

The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development by Reipert, B.M., Gangadharan, B., Hofbauer, C.J., Berg, V., Schweiger, H., Bowen, J., Blatny, J., Fijnvandraat, K., Mullins, E.S., Klintman, J., Male, C., McGuinn, C., Meeks, S.L., Radulescu, V.C., Ragni, M.V., Recht, M., Shapiro, A.D., Staber, J.M., Yaish, H.M., Santagostino, E., Brown, D.L.

“…Preventing factor VIII (FVIII) inhibitors following replacement therapies with FVIII products in patients with hemophilia A remains an unmet medical need…”
Get full text

The pattern of diagnosed HIV infection in Australia, 1984-1992 by McDonald, A M, Crofts, N, Blumer, C E, Gertig, D M, Patten, J J, Roberts, M, Davey, T, Mullins, S E, Chuah, J C, Bailey, K A

“…To describe the pattern of newly diagnosed HIV infection in Australia, between 1984 and 1992. State and Territory health authorities reported cases of newly…”
Get more information

The acquired immunodeficiency syndrome in Australia: incidence 1982-1991 by Kaldor, J, McDonald, A M, Blumer, C E, Gertig, D M, Patten, J J, Roberts, M, Walker, C C, Mullins, S E, Bailey, K A, Chuah, J C

“…To describe the incidence of the acquired immunodeficiency syndrome (AIDS) in Australia between 1982 and 1991. State and Territory Health Departments notified…”
Get more information

Real‐world experience with use of Antihemophilic Factor (Recombinant), PEG ylated for prophylaxis in severe haemophilia A by Dunn, A. L., Ahuja, S. P., Mullins, E. S.

“…Introduction Prophylaxis with extended half‐life factor VIII ( FVIII ) is approved for haemophilia A, but data regarding routine clinical use are limited. Aim…”
Get full text

Phase 1, single‐dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia by Gruppo, R. A., Malan, D., Kapocsi, J., Nemes, L., Hay, C. R. M., Boggio, L., Chowdary, P., Tagariello, G., Drygalski, A., Hua, F., Scaramozza, M., Arkin, S., Hermans, C. R. J. R., Claes, C., Hanes, I., Huyghe, I., Kantaridis, C., Costa, L. M., Ndongo, M.‐N., Petit, W., Santagostino, E. M., Cannavo, A., Fasulo, M. R., Mancuso, M. E., Tosetto, A., Castaman, G., Candiotto, L., Radossi, P., Scarpa, E., Smith, M. P., Dick, A. E., Robson, R. A., Waaka, D. S., Wynne, C. J., Punt, Z. E., Kavakli, K. R., Balkan, C., Duyu, M., Goksel, S., Karapinar, B., Ozyurek, A. R., Saydam, G., Karapinar, D. Y., Laffan, M., Millar, C. M., Suppiah, P. I., Rizleigh, C. K., Chowdary, G. P., Davies, J. S., Fosbury, E. L., Gill, S., Pike, G. N., Varghese Thachil, J., Recht, M., Deutsche, J., Taylor, J., Kalinyak, K. A., Mullins, E. S., Palumbo, J. S., Quinn, C. T., Tarango, C., Tarabar, S., Chandler, P. A., Deats, L., Deshpande, S. R., Epstein, N. U., Hansson, A. G., Pawlak, S. S., Rudin, D., Valentino, L. A. J., Kakodkar, N. C., Simpson, M. L., Fogarty, P. F., Bach, Tami L., Chiang, Elaine Y., Adamson, J. W., Glass, C. S., Sidhu, N., Tucker‐Greene, T. D.

“…Essentials Marzeptacog alfa (activated) [MarzAA] is a novel variant of activated human factor VII. A phase 1 dose escalation trial of MarzAA was conducted in…”
Get full text